BRPI0606707A2 - uréias dissubstituìdas como inibidores de quinase - Google Patents

uréias dissubstituìdas como inibidores de quinase

Info

Publication number
BRPI0606707A2
BRPI0606707A2 BRPI0606707-7A BRPI0606707A BRPI0606707A2 BR PI0606707 A2 BRPI0606707 A2 BR PI0606707A2 BR PI0606707 A BRPI0606707 A BR PI0606707A BR PI0606707 A2 BRPI0606707 A2 BR PI0606707A2
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
treatment
warm
disubstituted urea
Prior art date
Application number
BRPI0606707-7A
Other languages
English (en)
Inventor
Pascal Furet
Georg Martiny-Baron
Clive Mccarthy
Vittorio Rasetti
Andrea Vaupel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606707A2 publication Critical patent/BRPI0606707A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

URéIAS DISSUBSTITUìDAS COMO INIBIDORES DE QUINASE. A presente invenção refere-se a compostos da fórmula (1), seu uso como inibidores de quinase, novas fórmulações farmacêuticas que compreendem os ditos compostos, ditos compostos para uso no diagnóstico ou tratamento terapêutico de animais de sangue quente, especialmente seres humanos, seu uso no tratamento de doenças ou para a fabricação de fórmulações farmacêuticas úteis no tratamento de doenças que respondem à modulação de atividade de quinase, sendo que os métodos de tratamento compreendem administração de ditos compostos em um animal de sangue quente, especialmente um ser humano, e processos para a fabricação de ditos compostos.
BRPI0606707-7A 2005-01-10 2006-01-09 uréias dissubstituìdas como inibidores de quinase BRPI0606707A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500435.3A GB0500435D0 (en) 2005-01-10 2005-01-10 Organic compounds
PCT/EP2006/000098 WO2006072589A2 (en) 2005-01-10 2006-01-09 Disubstituted ureas as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0606707A2 true BRPI0606707A2 (pt) 2009-07-07

Family

ID=34203857

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606707-7A BRPI0606707A2 (pt) 2005-01-10 2006-01-09 uréias dissubstituìdas como inibidores de quinase

Country Status (12)

Country Link
US (1) US20090131437A1 (pt)
EP (1) EP1838700A2 (pt)
JP (1) JP2008526804A (pt)
KR (1) KR20070097493A (pt)
CN (1) CN101103023A (pt)
AU (1) AU2006204505A1 (pt)
BR (1) BRPI0606707A2 (pt)
CA (1) CA2592743A1 (pt)
GB (1) GB0500435D0 (pt)
MX (1) MX2007008372A (pt)
RU (1) RU2007130532A (pt)
WO (1) WO2006072589A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
JP5244369B2 (ja) 2006-11-10 2013-07-24 富士フイルム株式会社 ５−アミノピラゾール誘導体の製造方法、アゾ色素
KR20110070887A (ko) 2008-10-02 2011-06-24 레스피버트 리미티드 Ｐ38 엠에이피 키나제 억제제
GB0818033D0 (en) * 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP5670912B2 (ja) * 2008-12-11 2015-02-18 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
GB0905955D0 (en) * 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011025798A1 (en) * 2009-08-28 2011-03-03 Glaxosmithkline Llc Compounds and methods
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
EP2556068B1 (en) * 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
PE20142355A1 (es) 2011-10-03 2015-01-10 Respivert Ltd 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US20150225373A1 (en) * 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
CN104780929A (zh) 2012-09-11 2015-07-15 Slh最佳保健有限责任公司 牙齿清洁组合物
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
PT3357919T (pt) 2014-02-14 2020-02-20 Respivert Ltd Compostos heterocíclicos aromáticos como compostos antiinflamatórios
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032110A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
SK285371B6 (sk) * 1997-12-22 2006-12-07 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
US7041669B2 (en) * 2002-02-25 2006-05-09 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-benzofused urea compounds useful in treating cytokine mediated diseases
JP2007535565A (ja) * 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体

Also Published As

Publication number Publication date
KR20070097493A (ko) 2007-10-04
US20090131437A1 (en) 2009-05-21
RU2007130532A (ru) 2009-02-20
JP2008526804A (ja) 2008-07-24
EP1838700A2 (en) 2007-10-03
GB0500435D0 (en) 2005-02-16
MX2007008372A (es) 2007-08-21
WO2006072589A2 (en) 2006-07-13
CA2592743A1 (en) 2006-07-13
AU2006204505A1 (en) 2006-07-13
CN101103023A (zh) 2008-01-09
WO2006072589A3 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0507755A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
BRPI0510936A (pt) formulações com liberação controlada de substáncia ativa, contendo vardenafil
BRPI0517458A (pt) derivados da xantina com atividade para o receptor hm74a
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0606930A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente
WO2005007648A3 (en) Biaryl piperazinyl-pyridine analogues
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
DE602005023782D1 (de) Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit
BRPI0519135A2 (pt) macrolÍdeos
BR112021021242A2 (pt) Composições de medicamento à base de peptídeo de colágeno e dispositivos e métodos de produção e uso dos mesmos
SG157399A1 (en) Substituted biaryl piperazinyl-pyridine analogues
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
BRPI0509271A (pt) formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
SE0301369D0 (sv) Chemical compounds
WO2007076460A3 (en) Substituted thiazole ureas useful as inhibitors of protein kinases
BRPI0513953A (pt) métodos para tratamento de doenças ou distúrbios mediados pela ccr2

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.